Higgins M A, Berridge B R, Mills B J, Schultze A E, Gao H, Searfoss G H, Baker T K, Ryan T P
Department of Lead Optimization Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Greenfield, IN 46140, USA.
Toxicol Sci. 2003 Aug;74(2):470-84. doi: 10.1093/toxsci/kfg142. Epub 2003 May 28.
The safety of pharmaceuticals is typically assessed in the dog and rat prior to investigation in humans. As a result, a greater understanding of adverse effects in these preclinical testing species would improve safety assessment. Despite this need, there is a lack of tools to examine mechanisms and identify biomarkers in the dog. To address this issue, we developed an Affymetrix-based oligonucleotide microarray capable of monitoring the expression of thousands of canine genes in parallel. The custom canine array contains 22,774 probe sets, consisting of 13,729 canine and 9045 human-derived probe sets. To improve cross-species hybridization with human-derived probes, the detection region was moved from the variable 3' UTR to the more homologous coding region. Testing of this strategy was accomplished by comparing hybridization of naive dog liver RNA to the canine array (coding region design) and human U133A array (standard 3' design). Although raw signal intensity was greater with canine-specific probe sets, human-derived probes detected the expression of additional liver transcripts. To assess the ability of this tool to detect differential gene expression, the acute phase response was examined in beagle dogs given lipopolysaccharide (LPS). Hepatic gene expression 4 and 24 h post-LPS administration was compared to gene expression profiles of vehicle-treated dogs (n=3/group). Array data was consistent with an acute inflammatory response, with transcripts for multiple cytokines and acute phase proteins markedly induced 4 h after LPS challenge. Robust changes in the expression of transcripts involved with glucose homeostasis, biotransformation, and extracellular matrix remodeling were observed 24 h post-dose. In addition, the canine array identified several potential biomarkers of hepatic inflammation. Strong correlations were found between gene expression data and alterations in clinical chemistry parameters such as serum amyloid A (SAA), albumin, and alkaline phosphatase (ALP). In summary, this new genomic tool successfully detected basal canine gene expression and identified novel aspects of the acute phase response in dog that shed new light on mechanisms underlying inflammatory processes.
药物的安全性通常在用于人体研究之前先在狗和大鼠身上进行评估。因此,更深入了解这些临床前试验物种的不良反应将有助于改进安全性评估。尽管有此需求,但目前缺乏用于研究狗体内机制和识别生物标志物的工具。为解决这一问题,我们开发了一种基于Affymetrix的寡核苷酸微阵列,能够同时监测数千个犬类基因的表达。定制的犬类阵列包含22,774个探针组,其中包括13,729个犬类探针组和9045个人源探针组。为了提高与人源探针的跨物种杂交能力,将检测区域从可变的3'非翻译区移至同源性更高的编码区。通过比较未接触过抗原的狗肝脏RNA与犬类阵列(编码区设计)和人类U133A阵列(标准3'设计)的杂交情况来测试该策略。尽管犬类特异性探针组的原始信号强度更高,但人源探针检测到了更多肝脏转录本的表达。为了评估该工具检测基因表达差异的能力,我们在给予脂多糖(LPS)的比格犬中研究了急性期反应。将LPS给药后4小时和24小时的肝脏基因表达与给予赋形剂的狗(每组n = 3)的基因表达谱进行比较。阵列数据与急性炎症反应一致,LPS攻击后4小时,多种细胞因子和急性期蛋白的转录本明显诱导。给药后24小时观察到与葡萄糖稳态、生物转化和细胞外基质重塑相关的转录本表达发生了显著变化。此外,犬类阵列还鉴定出了几种肝脏炎症的潜在生物标志物。在基因表达数据与临床化学参数(如血清淀粉样蛋白A(SAA)、白蛋白和碱性磷酸酶(ALP))的变化之间发现了强相关性。总之,这种新的基因组工具成功地检测到了犬类的基础基因表达,并确定了狗急性期反应的新方面,为炎症过程的潜在机制提供了新的线索。